1. Erwin PC, Meschke LL, Ehrich SF, et al. Neonatal abstinence syndrome in East Tennessee: characteristics and risk factors among mothers and infants in one area of Appalachia. J Health Care Poor Underserved 2017;28:1393-1408.
2. Ko JY, Partick SW, Tong VT, et al. Incidence of neonatal abstinence syndrome-28 states, 1999-2013. MMWR Morb Mortal Wkly Rep 2016;65:799-802.
5. Olsen M, Walker JJ. Provision of buprenorphine to pregnant women by for-profit clinics in an Appalachian city. South Med J 2018;111:575-578.
6. Committee on Obstetric Practice. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017;130:e81-e94.
8. Weigand SL, Stringer EM, Stuebe AM, et al. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol 2015;125:363-368.
9. Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012;107( suppl 1 ):5-27.
10. Kermack A, Flannery M, Tofighi B, et al. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat 2017;74:1-6.
11. Meyer M, Phillips J. Caring for pregnant opioid abusers in Vermont: a potential model for non-urban areas. Prev Med 2015;80:18-22.
12. Molfenter T, Sherbeck C, Zehner M, et al. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. Subst Abuse Treat Prev Policy 2015;10:13.
13. Allen B, Harocopos A. Non-prescribed buprenorphine in New York City: motivations for use, practices of diversion, and experiences of stigma. J Subst Abuse Treat 2016;70:81-86.
14. Rizzo RA, Neumann AM, King SOC, et al. Parenting and concerns of pregnant women in buprenorphine treatment. MCN Am J Matern Child Nurs 2014;39:319-324.
15. Bell J, Towers CV, Hennessy MD, et al. Detoxification from opiate drugs during pregnancy. Am J Obstet Gynecol 2016;215:374.e1-e6.
16. Stewart RD, Nelson DB, Adhikari EH, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 2013;209:267.e1-e5.
17. Klaman SL, Isaacs K, Leopold A, et al. Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. J Addict Med 2017;11:178-190.
18. Winkelman TNA, Villapiano N, Kozhimannil KB, et al. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014. Pediatrics 2018;141:e20173520.
19. Corr TE, Hollenbeak CS. The economic burden of neonatal abstinence syndrome in the United States. Addiction 2017;112:1590-1599.
20. van Barr A, de Graaff BM. Cognitive development at preschool-age of infants of drug-dependent mothers. Dev Med Child Neurol 1994;36:1063-1075.
21. Sundelin Wahlsten V, Sarman I. Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatr 2013;102:544-549.
22. Fill MA, Miller AM, Wilkinson RH, et al. Educational disabilities among children born with neonatal abstinence syndrome. Pediatrics 2018;142:e20180562.